434 Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)

434 Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)

Bibliographic Details
Main Authors:	Elizabeth Evans, Crystal Mallow, Ernest Smith, Maurice Zauderer, Marya Chaney, Terrence Fisher, Amber Foster, John Leonard
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)
by: Elizabeth Evans, et al.
Published: (2023-11-01)

629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma
by: Brian Burns, et al.
Published: (2023-11-01)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
by: Lu Si, et al.
Published: (2022-10-01)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
by: Qu J, et al.
Published: (2020-07-01)

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
by: Lu Si, et al.
Published: (2019-06-01)

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
by: Byoung Chul Cho, et al.
Published: (2024-07-01)

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
by: Elizabeth E. Evans, et al.
Published: (2022-08-01)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
by: Åse Bratland, et al.
Published: (2023-11-01)

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
by: Seock-Ah Im, et al.
Published: (2024-09-01)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
by: Masaya Hattori, et al.
Published: (2023-05-01)

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
by: Irfan Cicin, et al.
Published: (2024-07-01)

Re: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study
by: Philippou, Y, et al.
Published: (2020)

Keynotes
Published: (2023-05-01)

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
by: Petrella, T, et al.
Published: (2017)

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
by: Shirish Gadgeel, MD, et al.
Published: (2022-11-01)

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
by: Arnulf Stenzl, et al.
Published: (2020-11-01)

Keynote speech
by: Dobson, F
Published: (1998)

Keynote talk.
by: Granger, R
Published: (2006)

Keynote Speakers
Published: (2023-12-01)

Keynote Article
by: Zervas Efthimios
Published: (2024-01-01)

Keynote Speakers
by: Challenging Glass
Published: (2024-06-01)

Keynote Speeches
by: Fenton Natalie, et al.
Published: (2020-03-01)

Keynote Speakers
by: Challenging Glass
Published: (2022-06-01)

Keynote Abstract
by: Mohd Dato’ Sabarudin, et al.
Published: (2016-01-01)

P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
by: S. Kümmel, et al.
Published: (2023-03-01)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
by: Koshiro Nishimoto, et al.
Published: (2022-05-01)

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
by: Andrea Necchi, et al.
Published: (2024-07-01)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
by: Antoni Ribas, et al.
Published: (2020-10-01)

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
by: Razvan Cristescu, et al.
Published: (2024-01-01)

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial
by: Philippe Merle, et al.
Published: (2023-02-01)

346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
by: Christian Poehlein, et al.
Published: (2020-11-01)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
by: J.M. Piulats, et al.
Published: (2020-07-01)

Keynotes in organic chemistry /
by: Parsons, A. F.
Published: (2014)

Keynotes in organic chemistry /
by: 212803 Parsons, Andrew F.
Published: (2003)

KEYNOTE: THE BIOGRAPHY OF OBJECTS
by: C. Greco
Published: (2019-05-01)

JIB434 – Biotechnology (Bioteknologi)
by: PPJJ, Pusat Pengajian Jarak Jauh
Published: (2019)

JIB434 – Biotechnology [Bioteknologi]
by: PPJJ, Pusat Pengajian Jarak Jauh
Published: (2018)

EEE 434 - Perhubungan Digit
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (1994)

RPG 434 - Perancangan Lalulintas
by: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Published: (1995)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
by: David G. Pfister, et al.
Published: (2023-03-01)